Comment on DOS-2026-0694-0008

The inclusion of a **Metabolic Lipid Panel** in DS-3026 warrants careful medical and legal justification because its primary purpose is to assess an individual's long-term cardiovascular risk rather than to identify conditions that pose a direct risk to public health. A metabolic lipid panel measures serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. These biomarkers are used to evaluate the risk of atherosclerotic cardiovascular disease (ASCVD), guide preventive interventions, and monitor the effectiveness of lipid-lowering therapy. Dyslipidemia is a chronic, non-communicable condition that is neither infectious nor transmissible. Elevated lipid levels increase the individual's future risk of cardiovascular events but do not create a risk of transmission or harm to other members of the public. Medical literature consistently recognizes lipid testing as a tool for individualized preventive medicine rather than communicable disease control. Clinical guidelines published by the American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), and the United States Preventive Services Task Force (USPSTF) recommend lipid testing to estimate an individual's cardiovascular risk and guide treatment decisions. These recommendations are intended to reduce future morbidity and mortality through long-term risk management and do not identify dyslipidemia as a condition requiring public health intervention to protect others. From both a medical and public health perspective, compulsory medical examinations are generally justified when they identify conditions that are communicable, require timely intervention to prevent transmission, or otherwise present a direct and demonstrable risk to the health or safety of the population. Dyslipidemia satisfies none of these criteria. It is not contagious, does not require isolation or contact tracing, and poses no immediate risk to other individuals. Consequently, a lipid panel primarily benefits the individual being examined rather than serving the traditional objectives of public health protection. The legal justification for requiring medical information should satisfy the principles of **necessity**, **proportionality**, and **legitimate purpose**. These principles are widely recognized in constitutional law, administrative law, public health law, human rights law, and data protection frameworks. Under these principles, any mandatory medical examination should be limited to information that is reasonably necessary to achieve a lawful objective. Where the stated objective is the protection of public health, there should be a demonstrable connection between the requested medical information and the prevention of a genuine public health risk. The principle of **medical necessity** requires that diagnostic testing be relevant to the purpose of the examination. The principle of **proportionality** requires that any interference with bodily integrity or medical privacy be no greater than necessary to accomplish that purpose. The principle of **data minimization**, reflected in numerous privacy and data protection frameworks, similarly requires that only information that is adequate, relevant, and limited to what is necessary for the stated purpose be collected. These principles recognize that compulsory medical testing constitutes an intrusion into an individual's bodily autonomy and informational privacy and therefore requires a clear and evidence-based justification. Because interpretation of lipid values depends upon age, sex, family history, diabetes, hypertension, smoking status, obesity, medication use, and overall cardiovascular risk, a lipid panel cannot reliably determine an individual's present health status in isolation. Rather, it serves as one component of long-term clinical risk assessment and preventive healthcare. It is not a diagnostic marker of communicable disease, nor is it an indicator of an immediate threat to public health. Accordingly, unless a specific statutory or regulatory objective can demonstrate that a metabolic lipid panel is necessary to achieve a legitimate governmental purpose beyond individualized preventive healthcare, its routine inclusion in DS-3026 appears difficult to justify under established principles of medical necessity, proportionality, purpose limitation, and evidence-based public health. If the objective of the examination is to identify conditions that pose a risk to the public, the relationship between lipid testing and that objective should be explicitly identified and supported by scientific evidence.